Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:OTLK NASDAQ:PYXS NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.00+1.4%$2.84$2.44▼$5.46$100.58M0.64147,267 shs76,116 shsOTLKOncobiologics$0.22+2.6%$0.31$0.16▼$3.39$23.15M0.325.06 million shs3.21 million shsPYXSPyxis Oncology$2.74+21.2%$1.59$0.97▼$5.55$172.21M1.43638,349 shs1.90 million shsVRCAVerrica Pharmaceuticals$7.99-3.0%$5.86$3.28▼$9.82$137.26M1.54128,547 shs110,359 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-3.27%-1.33%+10.04%0.00%+13.85%OTLKOncobiologics-6.95%-13.72%+1.27%-49.77%-84.70%PYXSPyxis Oncology-1.74%+32.94%+54.79%+49.67%+112.21%VRCAVerrica Pharmaceuticals-2.25%+29.36%+41.58%+19.25%+102.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.00+1.4%$2.84$2.44▼$5.46$100.58M0.64147,267 shs76,116 shsOTLKOncobiologics$0.22+2.6%$0.31$0.16▼$3.39$23.15M0.325.06 million shs3.21 million shsPYXSPyxis Oncology$2.74+21.2%$1.59$0.97▼$5.55$172.21M1.43638,349 shs1.90 million shsVRCAVerrica Pharmaceuticals$7.99-3.0%$5.86$3.28▼$9.82$137.26M1.54128,547 shs110,359 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-3.27%-1.33%+10.04%0.00%+13.85%OTLKOncobiologics-6.95%-13.72%+1.27%-49.77%-84.70%PYXSPyxis Oncology-1.74%+32.94%+54.79%+49.67%+112.21%VRCAVerrica Pharmaceuticals-2.25%+29.36%+41.58%+19.25%+102.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 2.25Hold$8.50183.33% UpsideOTLKOncobiologics 2.00Hold$4.501,933.44% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83149.39% UpsideVRCAVerrica Pharmaceuticals 1.75Reduce$17.00112.77% UpsideCurrent Analyst Ratings BreakdownLatest OTLK, PYXS, VRCA, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.004/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/7/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/31/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026PYXSPyxis Oncology Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.003/24/2026PYXSPyxis Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/11/2026OTLKOncobiologics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.003/9/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/18/2026OTLKOncobiologics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral2/18/2026OTLKOncobiologics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa BiosciencesN/AN/AN/AN/A$0.42 per shareN/AOTLKOncobiologics$205.70K112.55N/AN/A($0.60) per share-0.37PYXSPyxis Oncology$13.86M12.42N/AN/A$0.86 per share3.19VRCAVerrica Pharmaceuticals$35.58M3.86N/AN/A$1.55 per share5.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%5/27/2026 (Estimated)OTLKOncobiologics-$62.42M-$2.62N/AN/AN/AN/AN/A-293.47%5/14/2026 (Estimated)PYXSPyxis Oncology-$79.62M-$1.29N/AN/AN/AN/A-101.77%-69.81%5/8/2026 (Estimated)VRCAVerrica Pharmaceuticals-$17.89M-$1.58N/AN/AN/A-50.27%N/A-40.08%5/12/2026 (Estimated)Latest OTLK, PYXS, VRCA, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q2 2026ANIXAnixa Biosciences-$0.09N/AN/AN/AN/AN/A5/21/2026Q1 2026PYXSPyxis Oncology-$0.35N/AN/AN/A$10.94 millionN/A5/14/2026Q2 2026OTLKOncobiologics-$0.12N/AN/AN/A$4.39 millionN/A5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59N/AN/AN/A$4.51 millionN/A3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/11/2026Q4 2025VRCAVerrica Pharmaceuticals-$0.43-$0.51-$0.08-$0.57$4.52 million$5.09 million3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/A2/17/2026Q1 2026OTLKOncobiologics-$0.17-$0.22-$0.05-$0.38$3.14 million($1.21) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A12.1812.18OTLKOncobiologicsN/A0.350.28PYXSPyxis OncologyN/A3.413.41VRCAVerrica Pharmaceuticals0.032.592.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%OTLKOncobiologics11.20%PYXSPyxis Oncology39.07%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences26.40%OTLKOncobiologics2.80%PYXSPyxis Oncology10.60%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableOTLKOncobiologics20104.61 million101.69 millionOptionablePYXSPyxis Oncology6062.85 million56.19 millionOptionableVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataOTLK, PYXS, VRCA, and ANIX HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the ...May 6 at 5:58 PM | theglobeandmail.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5 at 4:05 PM | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5 at 3:50 PM | bakersfield.comBVerrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on TuesdayMay 5 at 1:06 PM | marketbeat.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5 at 8:00 AM | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateApril 30, 2026 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by BrokeragesApril 17, 2026 | marketbeat.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks ResearchApril 9, 2026 | marketbeat.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 19, 2026 | tmcnet.comVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 19, 2026 | businesswire.comVerrica Pharmaceuticals reports 2025 results and YCANTH sales growthMarch 16, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)March 12, 2026 | theglobeandmail.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 11, 2026 | finanznachrichten.deVerrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...March 11, 2026 | finance.yahoo.comVerrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call TranscriptMarch 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, PYXS, VRCA, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.00 +0.04 (+1.35%) As of 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Oncobiologics NASDAQ:OTLK$0.22 +0.01 (+2.60%) Closing price 04:00 PM EasternExtended Trading$0.22 +0.00 (+1.67%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Pyxis Oncology NASDAQ:PYXS$2.74 +0.48 (+21.24%) Closing price 04:00 PM EasternExtended Trading$2.66 -0.09 (-3.10%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Verrica Pharmaceuticals NASDAQ:VRCA$7.99 -0.25 (-3.03%) Closing price 04:00 PM EasternExtended Trading$7.75 -0.24 (-3.00%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
